AzTrials
AzTrials

Clostridium DifficilePhase 2/3NCT02466698

Intestinal Lavage for the Treatment of Severe C. Difficile Infections

A Phase 2/3 study testing Intestinal Lavage, Vancomycin and PEG in people with Clostridium Difficile, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 1 site in Canada.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Clostridium Difficile infections (CDIs) are treated initially with antibiotic therapy and supportive care, with surgical intervention reserved for patients with significant systemic toxicity or perforation. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Clostridium Difficile
What is being tested?
Intestinal Lavage, Vancomycin and PEG
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteCanada
Study dates
Aug 2016to Aug 2019
Phase
Phase 2/3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult (>= 18 years) inpatients at LHSC with symptomatic CDI (diarrhea or colonic ileus)
  • CDI confirmed by standard hospital microbiology lab testing
  • Patients must meet criteria for severe CDI, defined as either: white blood cell > 15,000 or Serum Creatinine > 1.5 times the pre-morbid level
  • Patients must have at least one additional risk factor for severity:
  • Fever >38.5 (if no other source of fever suspected) ii. Vasopressor requirement iii. Mechanical ventilation requirement iv. Serum lactate >5 mmol/L v. Colonic distension (>6cm transverse colon diameter on abdominal Xray or CT) vi. Colonic wall thickening, on abdominal Xray or CT, as reported by radiology. vii. Calculated ATLAS score ≥ 4

Who cannot join

  • The patient is deemed to have an immediate indication for surgery related to the diagnosis of CDI by the on call General Surgery service.
  • Pre-existing bowel discontinuity (e.g. ileostomy).
  • General Surgery service or most responsible care team deem the patient to have a contraindication to nasojejunal tube or fecal management system
  • Patients anticipated to be intolerant of the study regimen (e.g. severe ileus, unable to tolerate oral intake, etc.)

Trial locations and contacts

1 site in 1 country.

Tina E Mele, MD PhD contact

519-663-3970

tina.mele@lhsc.on.ca

Canada1 site, 1 recruiting
  • London Health Sciences Centre

    London, Ontario, N6A 5A5

    Tina Mele, MD, PhD, 519-663-3970, tina.mele@lhsc.on.ca

    Recruiting

Other trials in Canada

About this study

Official title: A Feasibility Randomized Trial of Intestinal Lavage for the Treatment of Severe C. Difficile Infections

Clostridium Difficile infections (CDIs) are treated initially with antibiotic therapy and supportive care, with surgical intervention reserved for patients with significant systemic toxicity or perforation. Severe CDI may be refractory to medical management and require surgical intervention, carrying a mortality of approximately 40%.

Mortality associated with CDI increases significantly as the severity of the infection increases. In patients failing medical management, earlier operation is associated with decreased mortality. However, the lack of validated tools to predict the necessity for surgical intervention, combined with the significant morbidity associated with total colectomy significantly reduces the likelihood of patients receiving early surgical intervention. The purpose of the proposed study is to assess the addition of intestinal PEG lavage via nasojejunal tube to usual care in the treatment of adult patients with severe CDI who have no immediate indication for surgical intervention.

Read the detailed description

Despite a lack of definitive evidence, total abdominal colectomy (TAC) is currently recommended as the surgical intervention of choice in the setting of severe-complicated CDI. This recommendation was based on meta-analysis of studies comparing TAC to partial colectomy or other surgery (such as exploratory laparotomy without colectomy, or ostomy formation) or no surgery, which did not find any statistical mortality difference. This recommendation is based on the results of sensitivity analysis and an expert panel consensus that considered the potential for confounding factors such as TAC occurring later in the course of the disease and on sicker patients, and on anticipated patient values that would pace value on a definitive procedure being the initial surgical intervention.

Given the high mortality of fulminant CDI, early surgical intervention is recommended. However, data regarding the optimal timing for surgical intervention is lacking. Meta-analyses and guidelines strongly recommend early surgical management, defined as being before the development of shock or the requirement for vasopressors, based on very low quality evidence, but with the potential for significant mortality reduction.

On the basis of CDI being a toxin mediated inflammatory process of the colonic mucosa, Neal et al hypothesized that surgical diversion of the fecal stream with a loop ileostomy and intraoperative antegrade colonic lavage may effectively treat severe CDI. Widely referred to as the 'Pittsburgh Protocol,' the regimen included colonic lavage with 8 litres of polyethylene glycol (PEG 3350) intra-operatively after formation of a loop ileostomy, followed by antegrade Vancomycin flushes (500mg in 500cc Ringer's Lactate TID) and IV Metronidazole (500mg TID) for 10 days. The study utilized a before-and-after methodology comparing the experimental protocol to historical controls. Forty-two patients were submitted to the regimen over 18 months. Three patients required reoperation for TAC. 30-day mortality was 19% in the intervention cohort, compared to 50% in the control. 79% of survivors went on to ileostomy reversal within 6 months of surgery. One of the potential benefits of this regimen is that given the reduced morbidity compared to TAC, practitioners may have been offering surgical intervention earlier in the management of CDI and not exclusively as a therapy of last resort. Despite the limited sample size and methodological shortcoming of this study, this treatment regime has been adopted in some centres for select cases. A randomized controlled trial to compare this less invasive surgical approach with total abdominal colectomy was closed prematurely given lack of meaningful patient enrolment (clinicaltrials.gov identifier NCT01441271).

Given the positive results of fecal diversion and antegrade lavage and vancomycin flushed proposed by Neal et al, combined with the limited data regarding the benefit of intracolonic vancomycin, a novel treatment was instituted at London Health Sciences Centre (LHSC) to accomplish lavage of the colon and vancomycin flushes in an antegrade fashion using a nasojejunal feeding tube to facilitate delivery in select patients. The protocol allows for lavage and intracolonic antibiotic delivery similar to that provided by the 'Pittsburgh protocol' without surgical fecal diversion.

A small preliminary cohort of patients completing this protocol at LHSC is being assessed retrospectively, comparing outcomes to a group undergoing the Pittsburgh protocol and initial total colectomy. The study was approved by the Western University Research Ethics Board (REB File # 104944). Interim analysis of the past 24 months includes 13 patients undergoing the study protocol, 9 undergoing the Pittsburgh protocol and 17 undergoing initial colectomy. Despite significant limitations of the study methodology, the results are encouraging and further study is warranted, especially given the significant mortality associated with fulminant CDI.

Being tested
Intestinal Lavage, Vancomycin, PEG, Metronidazole
Keywords
Colectomy, Surgical Procedures, Operative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Intestinal LavageProcedure or surgery

    Also called PEG Lavage

    A nasojejunal tube and fecal management system will be inserted. Intestinal lavage with PEG is initiated and increased to a goal rate of 400cc/hour to a total of 8L of PEG. In the absence of an ileus, lavage should be initiated at 200cc/hr. Tolerance is confirmed if the rectal effluent volume is ≥50% of the lavage volume over the first 6 hours and no emesis has developed. If the consulting surgical service suspects a significant ileus, the lavage is initiated at 100cc/hr. If tolerance is confirmed the lavage rate is increased in a stepwise fashion. Antibiotic regimen will consist of Vancomycin 500mg via nasojejunal every 6 hours and Metronidazole 500 mg IV three times daily for 14 days. PEG will be held for 2 hours after administration of Vancomycin.

  • VancomycinDrug

    Also called Antibiotic-V

    Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.

  • PEGDrug

    Also called Polyethylene glycol 3350

    Polyethylene glycol 3350, 8L in 48 hours, via a nasojejunal tube will be used to facilitate intestinal lavage.

  • MetronidazoleDrug

    Also called Antibiotic-M

    Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.

Study groups in NCT02466698
Study groupRoleWhat they receive
Intestinal LavageExperimentalA nasojejunal tube and fecal management system will be inserted. Intestinal lavage with PEG is initiated and increased to a goal rate of 400cc/hour to a total of 8L of PEG. In the absence of an ileus, lavage should be initiated at 200cc/hr. Tolerance is confirmed if the rectal effluent volume is ≥50% of the lavage volume over the first 6 hours and no emesis has developed. If the consulting surgical service suspects a significant ileus, the lavage is initiated at 100cc/hr. If tolerance is confirmed the lavage rate is increased in a stepwise fashion. Antibiotic regimen will consist of Vancomycin 500mg via nasojejunal every 6 hours and Metronidazole 500 mg IV three times daily for 14 days. PEG will be held for 2 hours after administration of Vancomycin.
Receives: Procedure: Intestinal Lavage; Drug: Vancomycin; Drug: PEG; Drug: Metronidazole
Usual CareActive comparatorPatients will receive usual care for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The usual care group will receive the same antibiotic doses as the experimental arm of the study. For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
Receives: Drug: Vancomycin; Drug: Metronidazole

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of eligible participants recruited into the study

    Recruited participants

    Measured: 12 months

Secondary outcomes (8)
  1. Number of participants meeting study inclusion criteria

    Included participants

    Measured: 12 months

  2. Number of participants who complete the assigned study protocol

    Completed study participants

    Measured: 12 months

  3. Number of participants who complete the treatment protocol without an adverse event

    Participants with no adverse events

    Measured: 12 months

  4. Number of participants with a complication or adverse event

    Participants with adverse events

    Measured: 12 months

  5. Number of participants who require initiation of mechanical ventilation following protocol initiation

    Participants requiring mechanical ventilation

    Measured: 12 months

  6. Number of participants who require operative intervention for CDI treatment

    Participants requiring operative intervention

    Measured: 12 months

  7. Surgeons' indication for operative intervention

    Surgeons will indicate the indication for operative intervention for any patient that is taken to the operating theatre for CDI treatment

    Measured: 12 months

  8. 30-day all-cause mortality

    Mortality within 30 days

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jun 2015 (estimated)
  2. Study startAug 2016
  3. Primary completionAug 2019 (estimated)
  4. Study completionAug 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02466698
Sponsor's protocol ID
106184
Status last verified
Aug 2018
First submitted
4 Jun 2015
Last updated
13 Aug 2018
Results posted
No
Data monitoring committee
No
Individual data sharing
Yes: De-dentified data available upon reasonable request after publication of study results

Publications

  • McCreery G, Jones PM, Kidane B, DeMelo V, Mele T; ERASE C. difficile (Early Rescue from Acute SEvere Clostridium difficile) Trials Group. Polyethylene glycol intestinal lavage in addition to usual antibiotic treatment for severe Clostridium difficile colitis: a randomised controlled pilot study. BMJ Open. 2017 Jul 31;7(7):e016803. doi: 10.1136/bmjopen-2017-016803.

    PubMed 28760801

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Intestinal Lavage, Vancomycin and PEG in people with Clostridium Difficile, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 13 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Tina E Mele, MD PhD (519-663-3970, tina.mele@lhsc.on.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of eligible participants recruited into the study (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02466698, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in